中国药业2025，Vol.34Issue(10)：100-103,4.DOI:10.3969/j.issn.1006-4931.2025.10.021
阿瑞匹坦联合昂丹司琼及地塞米松防治乳腺癌EC方案化疗所致恶心呕吐效果观察
Observation on the Efficacy of Aprepitant Combined with Ondansetron and Dexamethasone in the Pre-vention and Treatment of EC Regimen Chemotherapy Induced Nausea and Vomiting for Breast Cancer
摘要
Abstract
Objective To investigate the clinical efficacy and safety of aprepitant,ondansetron and dexamethasone triple antiemetic regimen in the prevention and treatment of chemotherapy-induced nausea and vomiting(CINV)for breast cancer.Methods A total of 104 patients with early breast cancer who received EC regimen(epirubicin+cyclophosphamide)chemotherapy after surgery in the hospital from April to May 2024 were selected and divided into dual therapy group and triple therapy group according to the random number table method,with 52 cases in each group.Both groups were given Ondansetron Hydrochloride Orally Disintegrating Tablets orally+Dexamethasone Acetate Injection intravenously,and the triple therapy group was additionally given Aprepitant Capsules.Results The incidence of acute vomiting in the triple therapy group was 3.85%,and the incidence of delayed vomiting was 3.85%,which was significantly lower than 17.31%and 30.77%in the dual therapy group(P<0.05).The total effective rate of delayed vomiting in the triple therapy group was 98.08%,which was significantly higher than 78.85%in the dual therapy group(P<0.05).Conclusion Compared with the dual antiemetic regimen of ondansetron and dexamethasone,the triple antiemetic regimen of aprepitant combined with ondansetron and dexamethasone is more effective in preventing and treating delayed vomiting caused by chemotherapy for breast cancer.关键词
阿瑞匹坦/乳腺癌/辅助化疗/EC方案化疗所致恶心呕吐/临床疗效Key words
aprepitant/breast cancer/adjuvant chemotherapy/EC regimen/chemotherapy-induced nausea and vomiting/drug combination分类
医药卫生引用本文复制引用
陶卓立,胡晓鹏,李兴睿..阿瑞匹坦联合昂丹司琼及地塞米松防治乳腺癌EC方案化疗所致恶心呕吐效果观察[J].中国药业,2025,34(10):100-103,4.基金项目
湖北省重点研发计划立项项目[2022BCA007]. （）
